Serina Cucuzza

Biography

 Serina Cucuzza, is the Executive GM Commercial Strategy, IP and External Affairs at the Burnet Institute. In this role she is involved in the commercialisation of novel technologies developed from the Institute’s research. This includes managing the Institute’s IP portfolio; sourcing funding (over $6 million to date); negotiating deals and managing spin out companies. Serina is also involved in projects of strategic importance to the Institute including biotechnology-related activities in China and is a director of Access Point of Care, a multi-national initiative that applies the Institute’s capabilities in novel point-of-care diagnostics in resource-constrained settings. Serina currently chairs the Burnet’s IP and Commercialisation Working Group and is secretary of the Board’s IP and Commercialisation sub-committee. She also sits on the Investment Review Committee of the Medical Research Commercialisation Fund, the Molecules to Medicines Steering Committee and the AusMedtech Victorian Branch Committee. She is the Company Secretary and Director of HepSeeVax Pty Ltd, and HepGenics Pty and a member of the Australian Institute of Company Directors.

Research Interest

 Molecular Medicines